Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
J Clin Microbiol. 2012 Feb;50(2):337-45. doi: 10.1128/JCM.01287-11. Epub 2011 Nov 23.
While viral load testing has gained widespread acceptance, a primary limitation remains the variability of results, particularly between different laboratories. While some work has demonstrated the importance of standardized quantitative control material in reducing this variability, little has been done to explore other important factors in the molecular amplification process. Results of 185 laboratories enrolled in the College of American Pathologists (CAP) 2009 viral load proficiency testing (PT) survey (VLS) were examined. This included 165 labs (89.2%) testing for cytomegalovirus (CMV), 99 (53.5%) for Epstein-Barr virus (EBV), and 64 (34.6%) for BK virus (BKV). At the time of PT, laboratories were asked a series of questions to characterize their testing methods. The responses to these questions were correlated to mean viral load (MVL) and result variability (RV). Contribution of individual factors to RV was estimated through analysis of variance (ANOVA) modeling and the use of backward selection of factors to fit those models. Selection of the quantitative calibrator, commercially prepared primers and probes, and amplification target gene were found most prominently associated with changes in MVL or RV for one or more of the viruses studied. Commercially prepared primers and probes and amplification target gene made the largest contribution to overall variability. Factors contributing to MVL and RV differed among viruses, as did relative contribution of each factor to overall variability. The marked variability seen in clinical quantitative viral load results is associated with multiple aspects of molecular testing design and performance. The reduction of such variability will require a multifaceted approach to improve the accuracy, reliability, and clinical utility of these important tests.
虽然病毒载量检测已经得到广泛认可,但一个主要的局限性仍然是结果的可变性,特别是在不同的实验室之间。虽然一些研究已经证明了标准化定量控制材料在减少这种可变性方面的重要性,但在探索分子扩增过程中的其他重要因素方面做得还很少。对参加美国病理学家学院(CAP)2009 年病毒载量能力验证(PT)调查(VLS)的 185 个实验室的结果进行了检查。这包括 165 个实验室(89.2%)检测巨细胞病毒(CMV),99 个实验室(53.5%)检测 EB 病毒(EBV),64 个实验室(34.6%)检测 BK 病毒(BKV)。在 PT 时,实验室被要求回答一系列问题,以描述他们的测试方法。对这些问题的回答与平均病毒载量(MVL)和结果可变性(RV)相关。通过方差分析(ANOVA)建模和使用因素的后向选择来拟合这些模型,估计了单个因素对 RV 的贡献。定量校准器、商业制备的引物和探针以及扩增靶基因的选择与所研究的一种或多种病毒的 MVL 或 RV 的变化最显著相关。商业制备的引物和探针以及扩增靶基因对整体变异性的贡献最大。影响 MVL 和 RV 的因素因病毒而异,每个因素对整体变异性的相对贡献也不同。临床定量病毒载量结果的显著可变性与分子检测设计和性能的多个方面有关。要减少这种可变性,需要采取多方面的方法来提高这些重要检测的准确性、可靠性和临床实用性。